Uncertainty-aware quantitative analysis of high-throughput live cell migration data

Simo Kitanovski[1,#], Shannon Conroy[2,#], Justin Sonneck[3,4,], Madeleine Dorsch[2,5,], Sebastian Urban[2,], Jianxu Chen[3,], Barbara M. Grüner[2,5,6,*], and Daniel Hoffmann[1,6,7,*]

[1]*Bioinformatics and Computational Biophysics, University of Duisburg-Essen, Essen, Germany.*
[2]*West German Cancer Center, Department of Medical Oncology, Cell Plasticity and Metastasis, University Duisburg-Essen, Essen, Germany.*
[3]*Leibniz-Institut für Analytische Wissenschaften - ISAS - e.V., Dortmund, Germany.*
[4]*Faculty of Computer Science, Ruhr-Universität Bochum, 44801, Bochum, Germany.*
[5]*German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany.*
[6]*Center for Medical Biotechnology, University of Duisburg-Essen, Essen, Germany.*
[7]*Center for Computational Sciences and Simulation, University of Duisburg-Essen, Essen, Germany.*
[#]*Co-first (simo.kitanovski@uni-due.de, shannon.conroy@uk-essen.de)*
[*]*Co-last and corresponding authors (barbara.gruener@uk-essen.de, daniel.hoffmann@uni-due.de)*

Abstract

Motivation: Accurate quantification of live cell migration, including velocity, is essential for understanding biological processes such as development,

immune function, and cancer metastasis. High-throughput migration assays generate complex, hierarchically structured datasets with technical noise, batch effects, and biological variability, introducing significant uncertainty into velocity estimates. Current statistical approaches often fail to rigorously quantify this uncertainty, undermining reproducibility and comparability across independent experimental datasets. To address this challenge, we present *cellmig*, a computational tool that employs Bayesian hierarchical modeling to separate biological signals from technical variation while explicitly quantifying uncertainty in migration velocity.
Results: cellmig provides a robust framework for analyzing cell migration assays, including dose-response studies and large-scale screens with multiple biological and technical replicates. By modeling biological variability (e.g., compound-dependent effects) and technical confounders (e.g., batch variability) within a unified Bayesian framework, cellmig estimates condition-specific effects on cell velocity with probabilistic uncertainty intervals, avoiding common pitfalls associated with null-hypothesis testing. Additionally, its generative models enable simulation of migration velocities under various assumptions, aiding experimental planning. In summary, cellmig enhances reproducibility, reliability, and biological insight in high-throughput migration studies, facilitating inter-dataset comparisons.
Availability and Implementation: cellmig is an open-source R package, freely available at: https://github.com/snaketron/cellmig
Contact: barbara.gruener@uk-essen.de, daniel.hoffmann@uni-due.de, simo.kitanovski@uni-due.de

Introduction

Cell migration is essential for many vital biological functions, for instance division or differentiation, and it impacts pathological processes including cancer metastasis (Aman and Piotrowski, 2010; Friedl and Gilmour, 2009; Luster et al., 2005; Reig et al., 2014). Diverse experimental methods have been developed aimed at quantifying different facets of cellular migration, including velocity, path linearity, average turning angle, time persistence or directional bias. These methods depend on a variety of variables, such as the cell type, exposure to chemical or physical stimuli and cell-cell interactions (Toscano et al., 2024).

The most common method for studying cell migration involves tracking cells with time-lapse microscopy followed by the acquisition of images at fixed time

intervals over several hours (Masuzzo et al., 2016; Toscano et al., 2024). A high-throughput version of this method facilitates the analysis of cell velocity across dozens of wells treated under different biological conditions (Cibir et al., 2023; Kramer et al., 2013). This is followed by computational image processing to extract quantitative cell velocities and to detect changes following perturbations such as drug treatments (Cibir et al., 2023; Hulkower and Herber, 2011). However, these workflows generate considerable technical noise (e.g., imaging artifacts, unprecise pipetting) and biological variability (e.g., cell-to-cell heterogeneity), and therefore technical and biological replicates are necessary, leading to large, hierarchically structured datasets: cells are nested within technical replicates that are nested within biological replicates (Lee et al., 2021; Masuzzo et al., 2013).

Current statistical analyses of such data rely on qualitative approaches, see e.g. Figure 3B from Masuzzo et al. (2016), or inadequate statistical methods, e.g., the nonparametric Wilcoxon rank-sum test (Kleino et al., 2025; Masuzzo et al., 2013; Shannon et al., 2024; Wiggins et al., 2023; Wortel et al., 2021). These approaches usually ignore the hierarchical structure of the data and fail to explicitly quantify uncertainty arising from technical or biological variability, reducing reproducibility. Similarly, to graphically represent the data, biologists typically quantify the velocity of cells from a single experiment, depict them in simple plots for each individual cell of that particular experiment and then describe the additional biological replicates without providing a graphical representation of the entire dataset (Dorsch et al., 2021). To address this gap, we present cellmig, an R package implementing Bayesian hierarchical models for migration analysis. cellmig quantifies condition-specific velocity changes (e.g., drug effects) while modeling nested data structures and technical artifacts, providing uncertainty-aware estimates through credible intervals. It further enables synthetic data generation for experimental design optimization. By integrating these features into an accessible tool, cellmig enhances reproducibility in migration studies, particularly for translational applications such as drug discovery. We demonstrate this by analyzing our own cell migration assays with over 30,000 cells and 20 biological conditions.

Materials and methods

Cell line and cultures

ASPC1 cells (ATCC Cat# CRL-1682, RRID:CVCL_0152, sex: female) were cultured under humified atmosphere at 37 °C and 5% CO_2 in DMEM high glucose, pyruvate (Gibco, Cat # 41966052) supplemented with 10% FBS (VWR/Biowest, Cat #S1600-500), 1% non-essential amino acids (ThermoFisher, Cat #11140035), 50 U/ml penicillin and 50 µg/ml streptomycin (ThermoFisher, Cat #10378016). Identity was authenticated by STR analysis. Testing to exclude mycoplasma contamination was performed regularly.

Chemicals

The following commercially available compounds were used at concentrations as indicated: fluvastatin (abcam, Cat# ab120651, CAS No 93957-55-2), pravastatin (Sigma-Aldrich, Cat# 524403, CAS No 81131-70-6), pitavastatin (Sigma Aldrich, Cat# SML2473, CAS No 147526-32-7), benproperine (Hycultech, Cat# HY114657A, CAS No 19428-14-9), haloperidol (Sigma Aldrich, Cat# H1512, CAS No 52-86-8), CK666 (Sigma Aldrich, Cat# SML0006, CAS No 442633-00-3), CK869 (Sigma Aldrich, Cat# C9124, CAS No 388592-44-7). All compounds were dissolved in DMSO (AppliChem, Cat# A3672, CAS No 67-68-5). The final concentration of DMSO for all compounds and vehicle control was at maximum 0.1% and serially diluted down in lower concentrations, except for pravastatin, where it was 1%, indicated by "DMSO high" (included as additional experimental vehicle control).

Assessment of *in vitro* viability

ASPC1 cells were seeded in triplicate per condition on 96-well plates (8×10^3 to 20×10^3 cells/well, depending on the time point). Compounds were added to ASCP1 cells at indicated concentrations. After 0, 24, 48 and 72 hours, cell viability was assessed using the PrestoBlue cell viability assay (Invitrogen, Cat #A13262) per manufacturer's instructions. Absorbance at 570 and 600 nm was measured with a Tecan Spark 10M plate reader (Tecan Trading AG, RRID:SCR_021897).

Live-cell imaging

96-well plates were coated with Collagen I (Sigma Aldrich, Cat #C8919, CAS No 9007-34-5) for 1 hour (at 37 °C and 5% CO_2), then washed once with PBS. Cells were seeded at 2,000 cells per well and incubated overnight. Cells were then treated with DMSO vehicle or respective compound for 48 hours prior to imaging. On each plate, four technical replicates per condition were imaged.

Time-lapse brightfield imaging was performed using a cell imaging multimode reader (Cytation 5, Agilent Technologies, RRID:SCR_019732). Each plate was imaged with the 20× objective for 4 hours at 37 °C and 5% CO_2 with a fixed number of kinetic reads/looping times as indicated. Individual images were aligned and stitched into .mp4 files using Gen5 software (RRID:SCR_017317). Videos of individual wells were excluded from further analysis if they were improperly aligned by Gen5 software or cell debris was misidentified as migrating cells.

Computational segmentation and tracking

The tracking workflow was established as previously described (https://doi.org/-10.1038/s41467-023-43765-3). The generated movies, exported as .mp4 files, underwent automated segmentation using the cellular segmentation tool Cellpose (https://doi.org/10.1038/s41592-020-01018-x). To adapt to the domain-specific characteristics of the ASPC1 cell line, a pretrained Cellpose model was fine-tuned using representative samples.

Subsequent single-cell tracking was carried out using a classical tracking algorithm based on the Earth Mover's Distance (https://doi.org/10.1007/978-3-319-10470-6_15). The tracking data contained unique tracking labels for each cell within the segmented images of the time-lapse sequence. Only cells in at least 10 consecutive frames were analyzed and reported as mean velocity pixel per frame. For each well, approximately 50–200 cells were measured in this way.

Computational processing of cell migration data

Cell migration data were processed using the programming language R (R Core Team, 2020), resulting in a table with 30,037 rows (individual cells) and multiple columns representing cell-specific features, including:

- mean cell velocity $y_i \in \mathbb{R}^+$

- well identifier, indexed as $w[i] \in \{1, 2, \ldots, 346\}$
- plate identifier, indexed as $p[w] \in \{1, 2, \ldots, 8\}$
- wells on plates $p \in \{1, 2, 3\}$ (generated as part of experiment A) and $p \in \{4, 5, 6, 7, 8\}$ (generated as part of experiment B) were each treated with the same sets of 13 treatments; in total, there are 20 distinct treatments, indexed by $t \in \{1, 2, \ldots, 20\}$, with only three treatments common to both plate groups
- each treatment represents a combination of a chemical compound and its administered concentration, applied across 4 wells per plate (referred to as technical replicates)

We observed between 10 and 275 cells per well (mean = 87 cells). Cell velocities ranged from 0.43 to 30.75 pixels/frame (mean velocity = 6.29 pixels/frame). Velocities on plates $p \in \{1, 2, 3\}$ were systematically lower compared to those on $p \in \{4, 5, 6, 7, 8\}$, attributable to slight differences in imaging configurations used for the two plate groups. This batch effect is corrected by our model, as described in the following sections.

Statistical modeling of cell migration velocity

We developed a Bayesian hierarchical regression model (M) to estimate treatment effects on cell migration velocity while accounting for experimental structure (technical/biological replicates, plate effects) and pooling information across groups.

This Bayesian approach is advantageous because it allows use of: (i) prior information (e.g. knowledge of effect magnitudes), (ii) explicit modeling of the experiment-specific structure (e.g. nested biological and technical replicates) and (iii) partial pooling of information across groups (Gelman et al., 2013).

Model structure

The observed migration velocity y_i for cell i was modeled using a gamma likelihood. The gamma distribution was chosen for the likelihood due to its flexibility in modeling positive, right-skewed data:

$$p(y_i|M) = \text{Gamma}(\kappa_{w[i]}, \lambda_{w[i]}) \tag{1}$$

where $w[i]$ is the index of well of cell i, and $\kappa_{w[i]} \in \mathbb{R}^+$ and $\lambda_{w[i]} \in \mathbb{R}^+$ are the shape and rate parameters of that cell. The mean ($\mu_{w[i]} \in \mathbb{R}^+$) of the gamma distribution is the ratio of $\kappa_{w[i]}$ to $\lambda_{w[i]}$, which allows reparameterization of the likelihood in terms of $\kappa_{w[i]}$ and $\mu_{w[i]}$ as:

$$p(y_{w[i]}|M) = \text{Gamma}(\kappa_{w[i]}, \frac{\kappa_{w[i]}}{\mu_{w[i]}}) \tag{2}$$

Accounting for experimental design

Each well w belongs to plate $p \in \{1, 2, \ldots, P\}$ (biological replicate) and is treated by treatment $t \in \{1, 2, \ldots, T\}$. Multiple wells per plate may receive the same treatment (technical replicates, indexed as $pt[w]$). The log-transformed means of well receiving the same treatment are modeled hierarchically, by treating the corresponding coefficients ($\log(\mu_{pt[w]})$) as random samples drawn from normal distributions:

$$\log(\mu_{pt[w]}) \sim \text{Normal}(\gamma_{pt}, \sigma_{tech}), \tag{3}$$

where γ_{pt} is mean effect of treatment t on plate p; and σ_{tech} captures the variability between technical replicates. However, we know that cell migration assays are affected by plate-specific batch effects that can systematically bias the migration velocity across all wells on the plates. To correct for plate-specific batch effects, we include an offset term α_p, defined as the mean migration velocity (on log-scale) of a control treatment (e.g., DMSO) on plate p, effectively normalizing batch effects across plates:

$$\begin{cases} \log(\mu_{pt[w]}) \sim \text{Normal}(\alpha_p, \sigma_{tech}), & \text{if } t \text{ is the control treatment} \\ \log(\mu_{pt[w]}) \sim \text{Normal}(\alpha_p + \gamma_{pt}, \sigma_{tech}), & \text{otherwise} \end{cases} \tag{4}$$

where the treatment effect γ_{pt} captures deviations from this baseline for treatment t on plate p; and σ_{tech} captures the variability between technical replicates.

Wells treated with the same treatment (t) will have similar cell migration velocities (similar γ_{pt} coefficients) after accounting for batch effects. Hence, the model treats γ_{pt} as random samples drawn from normal distributions:

$$\gamma_{pt} \sim \text{Normal}(\delta_t, \sigma_{bio}) \tag{5}$$

where δ_t is the overall (across plates) effects of treatment t on cell migration; and σ_{bio} is the standard deviation between biological replicates. The hierarchical

structure enables sharing of information across plates while preserving treatment-specific estimates.

We observed log-linear relationship between the means and variances of the gamma distributed velocities across wells (Supplementary Figure S1A), which is expected from the linear relationship between the mean ($\mu_w = \kappa_w / \lambda_w$) and variance ($\tau_w = \kappa_w / \lambda_w^2$) of the gamma distribution. The mean of the ratio, μ_w / τ_w, which is also the shape (λ_w) of the gamma distribution, was close to 0.7 (Supplementary Figure S1B). Using the relationship between the shape (λ_w) and rate (κ_w) of the gamma distribution, we expect that κ_w has a similar magnitude as μ_w:

$$\kappa_w = \lambda_w \cdot \mu_w \tag{6}$$

Hence, we assumed that values $\log(\kappa_w)$ are also approximately normally distributed, and treated them as random samples drawn from a normal distribution with mean μ_κ and standard deviation σ_κ:

$$\log(\kappa_w) \sim \text{Normal}(\mu_\kappa, \sigma_\kappa) \tag{7}$$

Quantifying treatment effects

For treatments i and j, the contrast $\rho_{ij} = \delta_i - \delta_j$ represents the log-fold change in migration velocity. If $\rho < 0$ and the 95% Highest Density Intervals (HDIs) of ρ lie mostly or completely below 0 (0 = null effect), we have strong evidence of reduced cell velocity in i relative to j. On the other hand, if ρ and the 95% HDI of ρ lie mostly or completely above 0, we have strong evidence of increased cell velocity in i compared to j. Distributions with the 95% HDIs more or less centered around 0 indicate that there is no evidence for a clear change in the cell velocity. Note that unclear evidence is not equivalent to no change, because for a treatment group with $\rho \approx 0$ we may also have a wide 95% HDI, including possibilities for positive or negative change. cellmig outputs mean and 95% HDI of ρ, including the probability of differential effect on migration (π):

$$\pi = 2 \cdot \max\left(\int_{\rho=-\infty}^{0} p(\rho)d\rho, \int_{\rho=0}^{\infty} p(\rho)d\rho\right) - 1 \tag{8}$$

Here, $\pi \approx 1$ indicates strong evidence for a difference in cell migration velocity between the treatments, while $\pi \approx 0$ suggests negligible evidence.

For easier interpretation, cellmig exponentiates the log-fold-changes described by: δ_t, γ_{pt}, and ρ_{ij}. This yields more easily accessible fold-changes described by: δ'_t, γ'_{pt}, and ρ'_{ij}.

Model priors

Our Bayesian approach requires prior distributions for the parameters α_p, δ_t, σ_{tech}, σ_{bio}, μ_κ, and σ_κ. We employed weakly informative priors that constrain parameters to plausible ranges while allowing the data to dominate posterior inferences. Using prior predictive checks, we ensured that the prior predictive distribution for the data has at least some density around extreme but plausible velocities (Supplementary Figure S2).

To assign a prior on α_p, we evaluated the log-transformed cell velocities in our dataset, which were approximately normally distributed with mean $\mu \approx 1.7$ and standard deviation $\sigma \approx 0.5$ (Supplementary Figure S1C). The well-specific mean velocities (on log-scale) were naturally encompassed within the distributions of the cell-specific velocities in both datasets. The parameter α_p represents the mean migration velocity of a control treatment (e.g., DMSO) on plate p, which we assume is also covered by the distribution of observed cell-specific velocities. To account for additional heterogeneity, we assign a prior on α_p which fully encompasses the observed distribution of log-transformed cell velocities Supplementary Figure S1C):

$$\alpha_p \sim \text{Normal}(1.7, 1) \tag{9}$$

Based on our knowledge about the similar magnitudes of μ_w and κ_w, we assumed that the overall mean of the population of κ_w (μ_κ) should be similar to the overall mean of the population of μ_w. Therefore, we assigned the same prior distribution to μ_κ:

$$\mu_\kappa \sim \text{Normal}(1.7, 1) \tag{10}$$

Meanwhile, δ_t represents the overall effect (generalized deflection from α_p) on cell migration associated with treatment group t. If we assume $\delta_t = 1$ and ignore the technical and biological variability in Equation 4 and 5, then from Equation 4 it follows that $\mu_{pt[w]} = \exp(\alpha_p) \cdot \exp(1)$, i.e. the mean cell velocity increases by a factor of $\exp(1) = 2.71$ over the baseline cell migration velocity of the plate. However, if $\delta_t = 2$, then the mean cell velocity would increase by a staggering factor of $\exp(2) = 7.38$ over the baseline migration. Using the control treatments in our experiments, we observed δ_t=-0.52 (95% HDI=[-0.45, -0.59]) for the compound CK666 at 40 µM, and δ_t=0.56 (95% HDI=[0.49, 0.64]) for fluvastatin at 10 µM, which are associated with severe reduction and increase in the cell migration velocity relative to DMSO (control treatment), respectively. Hence, for most treatments we expected $|\delta_t| < 1$, which implied that we need a

prior distribution that assigns high density to values around 0, and low density to values larger than 1 and smaller than -1. In fact, even if CK666 or fluvastatin were chosen as the the control treatment, $|\delta_t|$ barely crosses the magnitude 1. Nevertheless, to account for additional heterogeneity (e.g. from newly synthesized chemical compounds with stronger effect on cell migration), we assigned a normal distribution as prior on δ_t, with mean $\mu = 0$ and standard deviation $\sigma = 1$, which assigns 95% of the density to values between -1.95 and 1.95:

$$\delta_t \sim \text{Normal}(0, 1) \tag{11}$$

We used regularizing priors on the remaining scale parameters:

$$\begin{aligned} \sigma_{tech} &\sim \text{Normal}^+(0, 1) \\ \sigma_{bio} &\sim \text{Normal}^+(0, 1) \\ \sigma_{\kappa} &\sim \text{Normal}^+(0, 1) \end{aligned} \tag{12}$$

Experiment planning by simulation

Our Bayesian model (M) is generative and can simulate cell velocities using the same error model (Equation 1). In this framework, the values of $\kappa_{w[i]}$ and $\lambda_{w[i]}$ are drawn from their priors, which are themselves informed by parameters in subsequent layers of the model. This simulation process is critical for optimizing experimental design, particularly in determining the optimal number of (i) cells, (ii) technical replicates, and (iii) biological replicates. These factors directly affect the uncertainty in estimating treatment effects (δ_t) and their differences (ρ_{ij}). The model can operate in two modes: *fully* generative, where all free parameters are sampled from their priors, or *partially* generative, where certain parameters are fixed by the user (e.g., to align with estimates from prior experiments).

Results

Experimental design and computational workflow

To evaluate the performance of *cellmig* in quantifying treatment effects on cell migration velocity, additionally taking into account multiple experimental variables such as technical/biological replicates, plate variability, we conducted two independent high-throughput experiments (A and B) using pancreatic cancer cells ASPC1 (Fig. 1). This cell line was chosen as it exhibits robust migratory activity

in live-cell assays (Dorsch et al., 2021). Experiments A and B comprised three and five biological replicates, respectively. Each well of the 96-well plate was treated with one of eight compounds at specified concentrations. Each condition was tested in four technical replicates per plate and in at least three independent experiments. While experiments A and B tested largely distinct compound sets, both included the vehicle-only control (DMSO) on all plates at the highest DMSO concentration of the compound-treated conditions. Additional controls included a migration enhancer (fluvastatin 10 μM) and reducer (ARP2/3 complex inhibitor CK666 40 μM). Both enhancer and reducer were included to implement upper and lower baselines to be used for cross-plate comparison.

In experiment A, experimental compounds included three statins, pitavastatin, fluvastatin, and pravastatin–tested at 2.5, 5, and 10 μM–to allow for direct dose-response comparison. In this experiment, pitavastatin has a low solubility in DMSO. To therefore account for the higher concentrations of DMSO, "DMSO high" was included as an additional vehicle control setting. Experiment B included ARP2/3 inhibitors, and antipsychotics; two classes of compounds reported to reduce cellular migration due to altered actin cytoskeleton dynamics (Chen et al., 2016). ARP2/3 inhibitors, CK869, CK666 (Ilatovskaya et al., 2013) and benoproperine (Yoon et al., 2019)

The subsequent computational analysis included movie generation, data quality control, cell segmentation, and cell tracking, as described in the Methods section. Together, experiments A and B generated a structured dataset representative of high-throughput cell migration assays. The dataset was exported as a spreadsheet, describing the observed velocity of n cells (rows) and their experimental features (chemical compound, dose, plate identifier, well identifier), which was used as main input by cellmig to fit a hierarchical Bayesian model implemented in Stan Carpenter et al. (2017). Model inference was performed using the No-U-Turn sampler in the rstan R package (version 2.32.7), with four Markov chains run for 2,000 iterations each, including 1,000 warm-up iterations. To assess model validity, we performed posterior predictive checks, which showed that the simulated data were consistent with the observed data (Supplementary Figures S4 and S5). We evaluated convergence using the potential scale reduction factor (PSRF), the effective sample size (N_{eff}), and diagnostic information provided by rstan (e.g., divergence warnings during MCMC sampling). After having passed these tests, the posterior distributions of the model parameters were used to quantify differences in treatment effects including their uncertainties, as described in the following sections.

Overall treatment effects

Data was analyzed using cellmig, with DMSO as the reference for batch correction (Methods). The model reported overall treatment effects (δ_t) as log-fold-changes relative to DMSO (Fig. 2). Exponentiating δ_t yields interpretable fold-changes (vertical axis of Fig. 2), and we refer to these estimates as δ'_t, where δ'_t=1 indicates no change in treatment t relative to DMSO.

As expected, high-dose fluvastatin (10 µM) and CK666 (40 µM) showed strong positive (δ'_t=1.76, 95% HDI [1.63, 1.89]) and negative (δ'_t=0.59, 95% HDI [0.55, 0.64]) effects, respectively. Dose-response relationships were evident for control compounds: fluvastatin effects decreased to δ'_t=1.6, 95% HDI [1.47, 1.75] and δ'_t=1.37, 95% HDI [1.25, 1.49] at 5 µM and 2.5 µM, respectively, while CK666 effects decreased to δ'_t=0.78, 95% HDI [0.7, 0.88] and δ'_t=0.92, 95% HDI [0.82, 1.03] at 10 µM and 5 µM, respectively. High-dose DMSO caused a negligible velocity reduction (δ'_t=0.95, 95% HDI [0.87, 1.03]) with 95% HDIs overlapping the null effect (δ'=1).

Among the compounds, pitavastatin (2.5-10 µM) increased migration (δ'_t=1.47-1.7), whereas CK869 (δ'_t=0.67-0.75), benproperine (δ'_t=0.76-0.86), and haloperidol (δ'_t=0.81-0.86) reduced migration at 5 and 10 µM. We observed dose-dependent responses in these treatment groups as well. In contrast, pravastatin showed negligible effects across all doses (δ'_t=1.04-1.08) with 95% HDIs overlapping the null effect (δ'=1).

Quantifying non-treatment contributions to variation

cellmig further quantified plate-specific treatment effects (γ_{pt} for treatment t on plate p; Fig. 3B) relative to DMSO. As before, exponentiating γ_{pt} yielded interpretable fold-changes γ'_{pt} (vertical axis of Fig. 3B). While γ'_{pt} values generally mirrored the overarching δ'_t estimates, their variability across plates modeled by parameter σ_{bio} (Supplementary Figure S6B), accounted for biological heterogeneity in treatment responses. To assess batch correction efficacy, we compared γ'_{pt} distributions for shared treatments (e.g., fluvastatin at 10 µM) against raw plate-specific mean velocities (Fig. 3C). Despite systematic baseline differences between experiments – cells in experiment A exhibited higher raw velocities than those in experiment B (Fig. 3D: blue vs. orange dots) – γ'_{pt} coefficients for shared treatments converged to similar values after correction (Fig. 3B: blue vs. orange dots). In fact, the model parameters α_p accurately captured these inter-experiment biases (Supplementary Figure 6A): baseline velocities under DMSO were about

5-6 pixels/frame (experiment A) vs. 6-8 pixels/frame (experiment B).

Using the lowest-level model parameters $\mu_{pt[w]}$, representing uncorrected well-specific mean velocities, we quantified technical variability across replicates. The distribution of $\mu_{pt[w]}$ estimates and their 95% HDIs revealed well-to-well noise, modeled by parameter σ_{tech} (Supplementary Figure S6B). This granular quantification enables not only accurate evaluation of treatment effects on migration velocities but it also facilitates the design of cell-migration experiments: by decomposing biological and technical variability, cellmig informs requirements for replicates and sample sizes, answering questions such as: how many biological/technical replicates are needed to detect a target effect size (e.g., δ'_t or γ'_{pt}), or what is the minimum cell count per well for stable velocity estimates?

Quantitative comparison of treatment effects

Our model quantifies treatment effects (δ_t) relative to DMSO controls while enabling direct inter-treatment comparisons (e.g., between treatments i and j) through two key metrics: (1) fold change coefficients (ρ'_{ij}); (2) probabilities (π_{ij}) quantifying evidence for differential treatment effects.

Notably, pitavastatin (2.5-10 µM) demonstrated strong velocity enhancement, increasing migration by ρ'=1.7-2.3-fold compared to benproperine, CK869, and haloperidol (5-10 µM; red tiles, Fig. 4A). These comparisons showed maximal probability (π=1; gray tiles, Fig. 4B), indicating strong evidence for differential effects. In contrast, pravastatin (2.5-10 µM) exhibited weaker enhancement (ρ'=1.2-1.5-fold vs. suppressors; yellow tiles, Fig. 4A), consistent with its negligible effect relative to DMSO. The velocity-suppressing compounds – benproperine, CK869, and haloperidol – showed comparable effects across doses (ρ'=0.8-1.2-fold) with limited evidence for differential activity ($\pi < 1$). As expected, comparisons of treatment groups with themselves yielded $\rho' = 1$ and $\pi = 0$, indicating no difference in treatment effects (diagonal entries, Fig. 4A-B).

Discussion

We have developed a statistical model to rigorously quantify treatment-specific effects on cell migration velocity in high-throughput imaging assays. Our approach addresses key limitations of current methods by modeling hierarchical experimental designs and integrating sources of technical and biological variation into a unified Bayesian framework, implemented in the free, open source R

package cellmig.

Existing analytical pipelines for live-cell migration studies often rely on non-parametric tests or descriptive summaries that fail to account for replicate structure, batch effects, or uncertainty propagation. Such methods risk overinterpreting single experiments, conflating technical noise with biological signals, and producing irreproducible results. In contrast, cellmig employs a Bayesian hierarchical model to deliver probabilistic estimates of condition-specific effects while explicitly accommodating nested data structures (e.g., plates, wells, cells). This enables statistically robust comparisons across conditions with quantified uncertainty, reducing susceptibility to batch artifacts and improving reproducibility.

The reproducibility of our findings underscores the robustness of the method. Compounds targeting ARP2/3 complex-mediated actin nucleation – CK666 and CK869 (Cao et al., 2024) – consistently reduced migratory capacity in a dose-dependent manner. Similarly, benproperine, an inhibitor of the ARPC2 subunit of the ARP2/3 complex, demonstrated a comparable dose-dependent reduction in migration, consistent with prior observations (Yoon et al., 2019). Haloperidol, an antipsychotic drug previously shown to inhibit glioblastoma cell migration (Papadopoulos et al., 2020), also diminished migration in our screen, though to a lesser extent than the other compounds.

We previously reported that fluvastatin enhances pancreatic cancer cell migration by inducing a mesenchymal phenotype (Dorsch et al., 2021). Using cellmig, we not only confirmed its potent migration-inducing effect but also demonstrated a clear dose-dependent response mirrored by its analog, pitavastatin – both belonging to the same class of synthetic statins. In contrast, pravastatin, from the class of natural or fungal-derived derived statins, showed no effect on migration, suggesting that migration modulation may involve additional factors beyond HMG-CoA reductase inhibition.

Most importantly, cellmig enabled the direct and quantitative comparison of two completely independent experimental datasets, allowing for a rigorous assessment of compound-specific effects on migration and meaningful biological conclusions – an advancement not previously feasible

Another unique strength of cellmig is its generative capacity: the model can simulate synthetic datasets under user-defined assumptions, supporting power analysis and experimental design optimization. This feature is particularly valuable for resource-limited studies or large-scale screens, where balancing replicate numbers, batch configurations, and inferential precision is critical.

However, our approach has limitations. First, cellmig assumes data adhere to a predefined hierarchical structure (Supplementary Figure S7), which, while

common in high-throughput imaging, may not accommodate alternative designs (e.g., simpler studies without technical replicates; or more complex studies including unmodeled confounders) without redefining the model. Second, the current implementation focuses on mean migration velocity; while the framework is extensible to other phenotypes (e.g., persistence, directionality), such adaptations require additional methodological development.

In conclusion, cellmig addresses a critical gap in the analysis of live-cell migration assays. By combining hierarchical Bayesian modeling with tools for simulation and uncertainty quantification, it enhances the rigor, interpretability, and cross-study comparability of high-throughput migration data – advancements essential for both mechanistic research and translational applications such as drug discovery.

Funding

This work was supported by Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) grants HO 1582/12-1, GRK 2762 (subprojects M1 and M3) to D.H. and S.K., and Project-ID 424228829 – SFB1430 to B.M.G.

Acknowledgements

We would like to thank Eva Hahn and Nancy Meyer for technical assistance and members of the Grüner and Hoffmann groups for insightful discussions.



Figure 1: (Top) Live-cell imaging data is collected from multiple 96-well plates, each treated with matching controls (neutral, reducer, enhancer of migration) and unique experimental compounds in independent biological experiments. Still-frame images are captured at set intervals and stitched into a single video per well. (Bottom) To quantify single-cell migration velocity, videos undergo segmentation and tracking. The average velocity of each cell is calculated and exported as a spreadsheet for all experiments. cellmig enables quantification and cross-comparison of conditions using matching controls across plates.



Figure 2: Overall treatment effects on cell migration velocity. Mean (dot) and 95% highest density interval (HDI; error bars) of the overall treatment effects (δ'), defined as combinations of compound and dose. Horizontal dashed line indicates the null effect (δ'=1). Control compounds (DMSO, CK666, and fluvastatin) have white panels. The dotted gray rectangle encloses results for pitavastatin (at each concentration) and the corresponding control ("DMSO high").



Figure 3: Observations and multilevel treatment effects on cell migration velocity. (A) Mean (dot) and 95% highest density interval (HDI; error bars) of the plate-specific treatment effects (γ'). (B) Inferred mean (dot) and 95% HDI (error bars) of the cell migration velocity in individual wells ($\mu_{[w]}$) before correction for plate-effects. (C) Observed mean (over all cells) treatment-specific velocities on each plate. Blue and orange dots and error bars in panels A-C correspond to plates from two different plate groups. Horizontal dashed line indicates the null effect (γ'=1). Control compounds (DMSO, CK666, and fluvastatin) have white panels. The dotted gray rectangles mark pitavastatin (at each concentration) and the corresponding control ("DMSO high").



Figure 4: Differences in overall treatment effects. (A) Fold change (FC; described by parameter ρ'_{ij}) between overall treatments effects (δ_t) of row (i) vs. column (j) treatment groups. Tile colors and labels represent ρ'_{ij}. (B) Probability of differential treatment effect described by parameter π_{ij}. Tile colors and labels represent π_{ij}.

References

Andy Aman and Tatjana Piotrowski. Cell migration during morphogenesis. *Developmental biology*, 341(1):20–33, 2010.

Giovanni G Camici, Jan Steffel, Alexander Akhmedov, Nicola Schafer, Jeannette Baldinger, Urs Schulz, Kushiar Shojaati, Christian M Matter, Zhihong Yang, Thomas F Luescher, et al. Dimethyl sulfoxide inhibits tissue factor expression, thrombus formation, and vascular smooth muscle cell activation: a potential treatment strategy for drug-eluting stents. *Circulation*, 114(14):1512–1521, 2006.

LuYan Cao, Shaina Huang, Angika Basant, Miroslav Mladenov, and Michael Way. Ck-666 and ck-869 differentially inhibit arp2/3 iso-complexes. *EMBO reports*, 25(8):3221–3239, 2024.

Bob Carpenter, Andrew Gelman, Matthew D Hoffman, Daniel Lee, Ben Goodrich, Michael Betancourt, Marcus Brubaker, Jiqiang Guo, Peter Li, and Allen Riddell.

Stan: A probabilistic programming language. *Journal of statistical software*, 76 (1), 2017.

Mao-Liang Chen, Fu-Ming Tsai, Ming-Cheng Lee, and Yi-Yin Lin. Antipsychotic drugs induce cell cytoskeleton reorganization in glial and neuronal cells via rho/cdc42 signal pathway. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, 71:14–26, 2016.

Zülal Cibir, Jacqueline Hassel, Justin Sonneck, Lennart Kowitz, Alexander Beer, Andreas Kraus, Gabriel Hallekamp, Martin Rosenkranz, Pascal Raffelberg, Sven Olfen, et al. Complexeye: a multi-lens array microscope for high-throughput embedded immune cell migration analysis. *Nature Communications*, 14(1):8103, 2023.

Madeleine Dorsch, Manuela Kowalczyk, Mélanie Planque, Geronimo Heilmann, Sebastian Urban, Philip Dujardin, Jan Forster, Kristina Ueffing, Silke Nothdurft, Sebastian Oeck, et al. Statins affect cancer cell plasticity with distinct consequences for tumor progression and metastasis. *Cell Reports*, 37(8), 2021.

Peter Friedl and Darren Gilmour. Collective cell migration in morphogenesis, regeneration and cancer. *Nature reviews Molecular cell biology*, 10(7):445–457, 2009.

Andrew Gelman, John B Carlin, Hal S Stern, David B Dunson, Aki Vehtari, and Donald B Rubin. *Bayesian data analysis*. Chapman and Hall/CRC, 2013.

Keren I Hulkower and Renee L Herber. Cell migration and invasion assays as tools for drug discovery. *Pharmaceutics*, 3(1):107–124, 2011.

Daria V Ilatovskaya, Vladislav Chubinskiy-Nadezhdin, Tengis S Pavlov, Leonid S Shuyskiy, Viktor Tomilin, Oleg Palygin, Alexander Staruschenko, and Yuri A Negulyaev. Arp2/3 complex inhibitors adversely affect actin cytoskeleton remodeling in the cultured murine kidney collecting duct m-1 cells. *Cell and tissue research*, 354:783–792, 2013.

Iivari Kleino, Mats Perk, António GG Sousa, Markus Linden, Julia Mathlin, Daniel Giesel, Paulina Frolovaite, Sami Pietilä, Sini Junttila, Tomi Suomi, et al. Cellromer: an r package for clustering cell migration phenotypes from microscopy data. *Bioinformatics Advances*, page vbaf069, 2025.

Nina Kramer, Angelika Walzl, Christine Unger, Margit Rosner, Georg Krupitza, Markus Hengstschläger, and Helmut Dolznig. In vitro cell migration and invasion assays. *Mutation Research/Reviews in Mutation Research*, 752(1):10–24, 2013.

Rachel M Lee, Michele I Vitolo, Wolfgang Losert, and Stuart S Martin. Distinct roles of tumor associated mutations in collective cell migration. *Scientific reports*, 11(1):10291, 2021.

Andrew D Luster, Ronen Alon, and Ulrich H Von Andrian. Immune cell migration in inflammation: present and future therapeutic targets. *Nature immunology*, 6 (12):1182–1190, 2005.

Paola Masuzzo, Niels Hulstaert, Lynn Huyck, Christophe Ampe, Marleen Van Troys, and Lennart Martens. Cellmissy: a tool for management, storage and analysis of cell migration data produced in wound healing-like assays. *Bioinformatics*, 29(20):2661–2663, 2013.

Paola Masuzzo, Marleen Van Troys, Christophe Ampe, and Lennart Martens. Taking aim at moving targets in computational cell migration. *Trends in cell biology*, 26(2):88–110, 2016.

Fotios Papadopoulos, Rafaela Isihou, George A Alexiou, Thomas Tsalios, Evrysthenis Vartholomatos, Georgios S Markopoulos, Chrissa Sioka, Pericles Tsekeris, Athanasios P Kyritsis, and Vasiliki Galani. Haloperidol induced cell cycle arrest and apoptosis in glioblastoma cells. *Biomedicines*, 8(12):595, 2020.

R Core Team. *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing, Vienna, Austria, 2020. URL `https://www.R-project.org/`.

Germán Reig, Eduardo Pulgar, and Miguel L Concha. Cell migration: from tissue culture to embryos. *Development*, 141(10):1999–2013, 2014.

Michael J Shannon, Shira E Eisman, Alan R Lowe, Tyler FW Sloan, and Emily M Mace. cellplato–an unsupervised method for identifying cell behaviour in heterogeneous cell trajectory data. *Journal of Cell Science*, 137(20), 2024.

Elvira Toscano, Elena Cimmino, Fabrizio A Pennacchio, Patrizia Riccio, Alessandro Poli, Yan-Jun Liu, Paolo Maiuri, Leandra Sepe, and Giovanni Paolella. Methods

and computational tools to study eukaryotic cell migration in vitro. *Frontiers in Cell and Developmental Biology*, 12:1385991, 2024.

Laura Wiggins, Alice Lord, Killian L Murphy, Stuart E Lacy, Peter J O'Toole, William J Brackenbury, and Julie Wilson. The cellphe toolkit for cell phenotyping using time-lapse imaging and pattern recognition. *Nature Communications*, 14(1):1854, 2023.

Inge MN Wortel, Annie Y Liu, Katharina Dannenberg, Jeffrey C Berry, Mark J Miller, and Johannes Textor. Celltrackr: an r package for fast and flexible analysis of immune cell migration data. *ImmunoInformatics*, 1:100003, 2021.

Yae Jin Yoon, Young-Min Han, Jiyeon Choi, Yu-Jin Lee, Jieun Yun, Su-Kyung Lee, Chang Woo Lee, Jong Soon Kang, Seung-Wook Chi, Jeong Hee Moon, et al. Benproperine, an arpc2 inhibitor, suppresses cancer cell migration and tumor metastasis. *Biochemical pharmacology*, 163:46–59, 2019.